RT Journal Article
SR Electronic
T1 Effects of Theophylline on ADCY5 Activation - From Cellular Studies to Improved Therapeutic Options for ADCY5-Related Dyskinesia Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.24.22274941
DO 10.1101/2022.05.24.22274941
A1 Tänzler, Dirk
A1 Kipping, Marc
A1 Lederer, Marcell
A1 Günther, Wiebke F.
A1 Arlt, Christian
A1 Hüttelmaier, Stefan
A1 Merkenschlager, Andreas
A1 Sinz, Andrea
YR 2022
UL http://medrxiv.org/content/early/2022/06/04/2022.05.24.22274941.abstract
AB We show the effects of the three purine derivatives, caffeine, theophylline, and istradefylline, on the cAMP production of adenylyl cyclase 5 (ADCY5)-overexpressing cell lines. A comparison of cAMP levels was performed for ADCY5 wild-type and R418W mutant cells. ADCY5-catalyzed cAMP production was reduced with all three purines, while the most pronounced effects on cAMP reduction were observed for ADCY5 R418W mutant cells. The gain-of-function ADCY5 R418W mutant is characterized by an increased catalytic activity resulting in elevated cAMP levels, resulting in kinetic disorders or dyskinesia in patients. Based on our findings in ADCY5 cells, a slow-release formulation of theophylline was administered to a preschool aged patient with ADCY5-related dyskinesia. A striking improvement of symptoms was observed, outperforming the effects of caffeine that had previously been administered to the same patient.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00029154Funding StatementDFG (RTG 2467, project number 391498659: Intrinsically Disordered Proteins. Molecular Principles, Cellular Functions, and Diseases, RTG 2751: InCuPanC, project number 449501615, INST 271/404-1 FUGG, INST 271/405-1 FUGG, and CRC 1423, project number 421152132). The Federal Ministry for Economic Affairs and Energy (BMWi, ZIM project KK5096401SK0). Region of Saxony-Anhalt. Martin Luther University Halle-Wittenberg (Center for Structural Mass Spectrometry).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the University of Leipzig was informed and approved this study. The study has been registered at the DRKS (ID: DRKS00029154).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.